1 / 24
ISSN 2208-150X (Print)
ISSN 2208-1518 (Online)
THE BEST OF ASH 2017 CONFERENCE
Weekly Subcutaneous Emicizumab a New Standard of Care in Hemophilia Management•
bb2121 Anti-BCMA CAR T-Cell Therapy Leads to Durable Clinical Responses in Heavily Pretreated Relapsed/Refractory Multiple Myeloma• CTL019 Produces High 6-Month Response Rates in Highly Pretreated Adult Relapsed/Refractory
Diffuse Large B-Cell Lymphoma • BLU-285, a KIT D816V Inhibitor, Proves Promising in Advanced Systemic
Mastocytosis • The HbS Polymerization Inhibitor Voxelotor GBT440 Has Demonstrated Positive Initial Results
in Adolescents With Sickle Cell Disease
59TH AMERICAN SOCIETY OF HEMATOLOGY
(ASH) ANNUAL MEETING & EXPOSITION
9–12 DECEMBER 2017 • ATLANTA, GEORGIA, USA